Sanofi India Limited Stock Price Today (NSE: SANOFI)
Fundamental Score
Sanofi India Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sanofi India Limited share price today is ₹3169.20, up +1.66% on NSE/BSE as of 19 June 2026. Sanofi India Limited (SANOFI) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹10.03K (Cr). The 52-week high for SANOFI share price is ₹6410.00 and the 52-week low is ₹3054.00. At a P/E ratio of 27.17x, SANOFI is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 47.15% and a debt-to-equity ratio of 0.03.
Sanofi India Limited Share Price Chart — NSE/BSE Historical Performance
Sanofi India Limited share price chart: -6.06% return over the past month. 52-week high ₹6410.00, 52-week low ₹3054.00.
Sanofi India Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹3117.60 | ₹3179.50 | ₹3090.00 | ₹3169.20 | 25.81K (Cr) | |
| ₹3120.00 | ₹3183.30 | ₹3097.10 | ₹3117.60 | 30.59K (Cr) | |
| ₹3223.40 | ₹3250.00 | ₹3054.00 | ₹3097.10 | 76.92K (Cr) | |
| ₹3223.40 | ₹3223.40 | ₹3223.40 | ₹3223.40 | 0.00 (Cr) | |
| ₹3207.00 | ₹3236.70 | ₹3175.00 | ₹3223.40 | 28.54K (Cr) | |
| ₹3182.10 | ₹3222.10 | ₹3182.10 | ₹3197.50 | 18.65K (Cr) | |
| ₹3180.00 | ₹3199.50 | ₹3151.60 | ₹3181.90 | 51.53K (Cr) | |
| ₹3193.00 | ₹3218.50 | ₹3157.00 | ₹3163.20 | 53.54K (Cr) | |
| ₹3190.00 | ₹3215.30 | ₹3180.10 | ₹3191.00 | 18.21K (Cr) | |
| ₹3230.90 | ₹3230.90 | ₹3184.60 | ₹3190.00 | 19.54K (Cr) |
Sanofi India Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹3120.00 | ₹3183.30 | ₹3090.00 | ₹3169.20 | +1.58% | |
| ₹3405.00 | ₹3445.20 | ₹3054.00 | ₹3097.10 | -9.04% | |
| ₹3210.20 | ₹3560.66 | ₹3175.00 | ₹3407.20 | +6.14% | |
| ₹3900.00 | ₹3900.00 | ₹3160.00 | ₹3209.70 | -17.70% | |
| ₹4063.20 | ₹4153.30 | ₹3956.00 | ₹3965.10 | -2.41% | |
| ₹4096.50 | ₹4241.00 | ₹3976.00 | ₹4017.70 | -1.92% | |
| ₹4399.00 | ₹4434.30 | ₹4051.00 | ₹4087.20 | -7.09% | |
| ₹4825.00 | ₹4832.00 | ₹4350.10 | ₹4387.70 | -9.06% | |
| ₹4670.00 | ₹4898.00 | ₹4629.10 | ₹4780.60 | +2.37% | |
| ₹5145.00 | ₹5175.50 | ₹4623.50 | ₹4650.00 | -9.62% | |
| ₹5801.00 | ₹5801.00 | ₹5025.50 | ₹5144.00 | -11.33% | |
| ₹6371.50 | ₹6371.50 | ₹5742.00 | ₹5825.00 | -8.58% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Sanofi India Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sanofi India Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SANOFI across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (47.15%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (49.16%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (25.01%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (336.47x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹2441.60 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (60.40%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 27.85%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Revenue Contraction (-9.27%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-8.10% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-0.44% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-0.44% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Sanofi India Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Sanofi India Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Sanofi India LimitedSanofi India Li...Selected✓ SANOFI • 500674 | 49/100 | ₹3169.20₹3169 | ₹10032.97₹10032.97 | 27.17Average 27.2 Average | 47.15%Excellent 47.15% Excellent | 49.16%Excellent 49.16% Excellent | 0.03Excellent 0.0 Excellent | -0.44%Poor -0.44% Poor | -8.10%Poor -8.10% Poor | 2.68% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Sanofi India Limited PE Ratio History
Historical price-to-earnings ratio for SANOFI — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹179.46 | ₹6122.65 | 34.1x |
| FY 2023 | ₹261.78 | ₹8067.55 | 30.8x |
| FY 2022 | ₹269.47 | ₹5853.05 | 21.7x |
| FY 2021 | ₹410.06 | ₹7887.20 | 19.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Sanofi India Limited Dividend History
Annual cash dividends paid by SANOFI — dividend yield 2.68%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2024 | ₹384.60 Cr |
| FY 2023 | ₹868.30 Cr |
| FY 2022 | ₹1573.00 Cr |
| FY 2021 | ₹840.60 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Sanofi India Limited Quarterly Performance
Latest quarterly metrics for SANOFI — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-9.27%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
15.54%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-8.10%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-0.44%
Compounded annual net profit growth over 5 years
Sanofi India Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SANOFI — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Sanofi India Limited Financial Statements
Annual income statement, balance sheet and cash flow for Sanofi India Limited (SANOFI) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Sanofi India Limited
About SANOFI (Sanofi India Limited)
Sanofi India Limited is a prominent player in the Indian pharmaceutical landscape, committed to advancing healthcare solutions that cater to diverse medical needs. With a robust po...rtfolio spanning various therapeutic areas, the company focuses on delivering innovative and high-quality medicines to patients across India and select international markets. Sanofi India blends its global expertise with a deep understanding of local healthcare challenges, enabling it to address unmet medical needs and contribute to improved patient outcomes. Through strategic collaborations, research and development initiatives, and a dedicated workforce, Sanofi India strives to strengthen its position as a trusted partner in healthcare, promoting wellness and enhancing the quality of life for individuals and communities. The company's dedication to innovation and patient-centricity is reflected in its diverse product offerings. Focusing on areas such as metabolic disorders, cardiovascular diseases, and central nervous system disorders, Sanofi India provides a range of prescription drugs and consumer healthcare products designed to manage chronic conditions and address acute illnesses. Sanofi India endeavors to provide holistic healthcare solutions that improve patient adherence, efficacy, and accessibility. The company invests in cutting-edge technologies and advanced manufacturing processes to ensure the highest standards of quality and safety. With a strong commitment to ethical business practices and regulatory compliance, Sanofi India operates with integrity and transparency, building trust and confidence among healthcare professionals, patients, and stakeholders. Sanofi India remains committed to expanding its reach and impact through strategic partnerships and collaborations. By forging alliances with leading research institutions, healthcare providers, and industry organizations, the company aims to accelerate the development and commercialization of innovative therapies. Sanofi India's goal is to contribute to the advancement of medical knowledge and improve patient care in India and beyond. The company also places a strong emphasis on sustainable business practices, environmental responsibility, and social impact, demonstrating its commitment to creating a healthier and more equitable future for all. Sanofi India strives to be a responsible corporate citizen, contributing to the economic and social well-being of the communities in which it operates.
Company Details
Key Leadership
Corporate Events
SANOFI Share Price: Frequently Asked Questions
What is the current share price of Sanofi India Limited?
Sanofi India Limited (SANOFI) trades at ₹3169.20 on NSE and BSE. Market cap ₹10.03K (Cr). Educational data only.
What is the P/E ratio of Sanofi India Limited?
Sanofi India Limited has a P/E of 27.17x vs industry average 31.77x.
What is the Bull Run score for Sanofi India Limited?
Sanofi India Limited has a Bull Run score of 49/100 based on 25+ financial parameters.
Does Sanofi India Limited pay dividends?
Sanofi India Limited has a dividend yield of 2.68%. Past dividends don't guarantee future payments.
What is the ROE of Sanofi India Limited?
Sanofi India Limited has ROE of 47.15%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Sanofi India Limited?
Sanofi India Limited has debt-to-equity of 0.03.
Is Sanofi India Limited a good investment?
Bull Run gives Sanofi India Limited a score of 49/100. This is not investment advice — consult a SEBI-registered advisor.